# Step 163 - First-Tier Triad Operationalization Scope Review

**Step 163 is a governed operationalization-scope review only. It does not authorize or implement Step 164.**

Step 162 was verified as PASS with three equal first-tier tracks, nine synthetic scenarios, SHA-256 evidence integrity, fail-closed No-Bind behavior, backup and recovery, display-only RAMAT contracts, and no regulated execution.

## Locked doctrine

- Platform B v1 remains ARCHITECTURE LOCKED.
- Thread D v1 remains ARCHITECTURE LOCKED.
- Advanced shared evaluation belongs only to Platform B1 / MVP2.
- Thread D2 and RAMAT Vision remain DISPLAY / WITNESS ONLY.
- Qualified humans and authorized organizational roles retain binding authority.
- Official records and execution remain in governed source systems.
- IRLT, compounding pharmacy, and DSCSA remain equal first-tier tracks.
- No production integration, write-back, PHI, physical execution, or real wearable integration is authorized.

## Commercial operationalization tracks

| Track | Priority | Commercial output | Implementation status |
|---|---|---|---|
| OP-COMPOUNDING - Compounding Pharmacy Commercial Demonstration Pack | FIRST-TIER | Compounding Assurance Passport, ingredient genealogy view, pharmacist readiness view, and defensible preparation reconstruction | PROPOSED STEP 164 SCOPE - NOT IMPLEMENTED |
| OP-DSCSA - DSCSA Commercial Demonstration Pack | FIRST-TIER | DSCSA Assurance Passport, chain-of-custody truth view, trading-partner passport, and suspect-product investigation reconstruction | PROPOSED STEP 164 SCOPE - NOT IMPLEMENTED |
| OP-IRLT - IRLT Commercial Demonstration Pack | FIRST-TIER | IRLT Assurance Passport, live time-risk view, custody truth chain, and regulator-ready reconstruction package | PROPOSED STEP 164 SCOPE - NOT IMPLEMENTED |

## Operationalization-track details

### OP-COMPOUNDING - Compounding Pharmacy Commercial Demonstration Pack

- Strategic position: Equal first-tier commercialization and demonstration priority
- Operational pain point: A preparation may appear complete while prescription, patient, formula, ingredient, calculation, equipment, environmental, labeling, timing, or pharmacist dependencies disagree.
- Proposed demonstration: Synthetic prescription-to-dispensing readiness passport covering order identity, formula version, ingredient genealogy, calculations, preparation, labeling, beyond-use timing, pharmacist authority, and dispensing readiness.
- Step 162 kernel reuse: Identity; evidence sealing; rehash verification; dependency evaluation; authority evaluation; temporal validity; No-Bind; admissibility; RAMAT display contract; reconstruction
- Proposed new capabilities: Formula dependency graph; ingredient genealogy; calculation verification; label comparison; beyond-use timing; pharmacist review passport
- Required failure proof: Order mismatch, wrong formula, unreleased ingredient, calculation conflict, label mismatch, expired beyond-use time, or missing pharmacist authority must create a hold.
- Required success proof: All synthetic prescription, formula, ingredient, calculation, label, timing, and pharmacist-authority conditions must be satisfied before ACTION ADMISSIBLE.
- Human authority: Authorized prescriber context, qualified compounding personnel, authorized pharmacist, and accountable pharmacy management
- Source-system boundary: Mock pharmacy, formulation, inventory, equipment, environmental, label, and dispensing systems remain authoritative.
- RAMAT role: DISPLAY / WITNESS ONLY for order identity, formula, ingredients, calculation, timing, label, authority, and No-Bind state
- Commercial output: Compounding Assurance Passport, ingredient genealogy view, pharmacist readiness view, and defensible preparation reconstruction
- Authorization state: **NOT AUTHORIZED**

### OP-DSCSA - DSCSA Commercial Demonstration Pack

- Strategic position: Equal first-tier commercialization and demonstration priority
- Operational pain point: A serialized product may appear transferable while serial, lot, aggregation, EPCIS, transaction evidence, trading-partner authority, custody, or suspect-product state is unresolved.
- Proposed demonstration: Synthetic manufacturer-to-dispenser assurance passport covering serialization, EPCIS event sequence, aggregation, transaction evidence, trading-partner authority, custody, verification, suspect-product hold, and disposition readiness.
- Step 162 kernel reuse: Canonical identity; evidence sealing; rehash verification; source agreement; authority evaluation; No-Bind; admissibility; RAMAT display contract; reconstruction
- Proposed new capabilities: Serial and lot graph; EPCIS event-chain verification; aggregation integrity; trading-partner passport; suspect-product workflow; transaction evidence passport
- Required failure proof: Serial mismatch, broken aggregation, missing EPCIS event, unauthorized trading partner, incomplete transaction evidence, or suspect-product state must create a governed hold.
- Required success proof: Serialization, EPCIS, aggregation, partner authority, transaction evidence, custody, and suspect-product clearance must be satisfied before ACTION ADMISSIBLE.
- Human authority: Authorized manufacturer, trading-partner, supply-chain, compliance, investigation, Quality, and disposition roles
- Source-system boundary: Mock serialization, EPCIS, ERP, warehouse, trading-partner, verification, and investigation systems remain authoritative.
- RAMAT role: DISPLAY / WITNESS ONLY for product identity, event-chain integrity, partner authority, suspect-product state, No-Bind, and transfer readiness
- Commercial output: DSCSA Assurance Passport, chain-of-custody truth view, trading-partner passport, and suspect-product investigation reconstruction
- Authorization state: **NOT AUTHORIZED**

### OP-IRLT - IRLT Commercial Demonstration Pack

- Strategic position: Equal first-tier commercialization and demonstration priority
- Operational pain point: Time-critical radiopharmaceutical work can appear complete in one system while release, custody, timing, equipment, material, or receiving dependencies remain unresolved.
- Proposed demonstration: AURORA-17 batch-to-administration assurance passport covering manufacturing, QC, human release authority, decay window, custody transfer, transport, receipt, and administration readiness.
- Step 162 kernel reuse: Identity; SHA-256 sealing; rehash verification; dependency evaluation; authority evaluation; temporal validity; No-Bind; admissibility; RAMAT display contract; reconstruction
- Proposed new capabilities: Time-to-expiry engine; custody event sequence; transport-condition evidence; receiving-site readiness; decay-window risk state; IRLT evidence passport
- Required failure proof: Expired decay window, custody gap, wrong receiving site, evidence mismatch, or unavailable release authority must create ACTION HELD and NO-BIND STATE ACTIVE.
- Required success proof: All evidence, timing, identity, custody, authority, and receiving dependencies must be positively satisfied before ACTION ADMISSIBLE.
- Human authority: Authorized batch releaser, Quality Unit, radiation-safety role, logistics custodian, receiving-site authority, and qualified clinical personnel
- Source-system boundary: Mock MES, LIMS, eQMS, ERP, custody, transport, and administration systems remain authoritative.
- RAMAT role: DISPLAY / WITNESS ONLY for timing, identity, evidence, custody, authority, No-Bind, and human-action prompts
- Commercial output: IRLT Assurance Passport, live time-risk view, custody truth chain, and regulator-ready reconstruction package
- Authorization state: **NOT AUTHORIZED**

## Shared operationalization capabilities

| ID | Capability | Purpose |
|---|---|---|
| SHARED-163-01 | First-Tier Scenario Registry | Register IRLT, compounding pharmacy, and DSCSA scenarios through one governed schema. |
| SHARED-163-02 | Shared Assurance Evaluation Contract | Standardize identity, evidence, dependency, authority, timing, No-Bind, and admissibility inputs and outputs. |
| SHARED-163-03 | Read-Only Local Assurance API | Expose synthetic evaluation, status, passport, display, and reconstruction endpoints without source-system writes. |
| SHARED-163-04 | Evidence Passport Generator | Generate portable synthetic identity, provenance, integrity, dependency, authority, and decision packages. |
| SHARED-163-05 | RAMAT Display Feed | Provide expiring, redacted, display-only assurance contracts for each first-tier track. |
| SHARED-163-06 | Failure Injection Harness | Deterministically introduce identity, integrity, dependency, authority, timing, and source-state failures. |
| SHARED-163-07 | Governance Reconstruction Export | Export chronology, evidence references, decisions, No-Bind events, human prompts, and unresolved gaps. |
| SHARED-163-08 | Commercial Demonstration Launcher | Run controlled baseline, failure, hold, recovery, and admissibility demonstrations for each track. |
| SHARED-163-09 | Shared Test and Integrity Manifest | Generate repeatable tests, audit evidence, backup verification, and SHA-256 artifact integrity. |
| SHARED-163-10 | Human Authorization and Source-Execution Boundary | Ensure every admissible state still requires qualified human decision and governed source-system execution. |

## Governance gates

| Gate | Requirement | Status |
|---|---|---|
| GATE-163-01 - Explicit Step 164 Authorization | An accountable human must explicitly authorize Step 164 after reviewing Step 163. | REQUIRED |
| GATE-163-02 - Equal First-Tier Preservation | IRLT, compounding pharmacy, and DSCSA remain equal first-tier tracks. | REQUIRED |
| GATE-163-03 - Platform B v1 Lock | Platform B v1 remains limited to its six frozen capabilities. | LOCKED |
| GATE-163-04 - Thread D v1 Lock | Thread D v1 remains unchanged. | LOCKED |
| GATE-163-05 - Platform B1 Ownership | Shared advanced evaluation and operationalization logic belongs only to Platform B1 / MVP2. | REQUIRED |
| GATE-163-06 - RAMAT Display-Only Boundary | Thread D2 and RAMAT Vision remain DISPLAY / WITNESS ONLY. | REQUIRED |
| GATE-163-07 - Read-Only Integration Boundary | Any Step 164 local API must be synthetic and read-only with no production write-back. | REQUIRED |
| GATE-163-08 - Human Binding Authority | Qualified humans and authorized organizational roles retain binding authority. | REQUIRED |
| GATE-163-09 - Official Source-System Authority | Official records and execution remain in governed source systems. | REQUIRED |
| GATE-163-10 - Synthetic Data Boundary | Step 164 may use synthetic records and mock identities only. | REQUIRED |
| GATE-163-11 - No-Bind Fail-Closed Requirement | Missing, stale, conflicted, invalid, or compromised conditions must create or preserve a hold. | REQUIRED |
| GATE-163-12 - Hashing and Rehashing Requirement | Evidence integrity, SHA-256 sealing, rehashing, and tamper detection remain mandatory. | REQUIRED |
| GATE-163-13 - Security and Recovery Requirement | Step 164 must include tests, audit evidence, backup or reset, recovery, and integrity verification. | REQUIRED |
| GATE-163-14 - No Physical or Regulated Execution | No release, dispensing, administration, shipment, product transfer, or other regulated execution is authorized. | REQUIRED |

## Proposed Step 164 scope

- Proposed title: First-Tier Triad Assurance Orchestrator and Evidence Passport API
- Purpose: Implement one local synthetic orchestration layer over the Step 162 shared kernel that can launch controlled commercial demonstrations, expose read-only assurance state, generate evidence passports, issue RAMAT display feeds, inject governed failures, and export reconstruction packages for IRLT, compounding pharmacy, and DSCSA.
- Authorization state: **NOT AUTHORIZED**
- Authorization reason: Step 164 requires a new explicit accountable-human authorization after Step 163 review.

### Required Step 164 capabilities

- Shared scenario registry
- Strict JSON input and output schema
- Read-only localhost assurance API
- Commercial demonstration launcher
- Evidence passport generator
- RAMAT display-only feed
- Failure-injection harness
- Governance reconstruction export
- Audit event journal
- SHA-256 artifact-integrity manifest
- Deterministic unit and integration tests

### Required commercial demonstrations

- IRLT time or custody failure and recovery
- Compounding formula, label, or timing failure and recovery
- DSCSA serialization, EPCIS, partner, or suspect-product failure and recovery

### Explicit exclusions

- No Platform B v1 modification
- No Thread D v1 modification
- No production source-system connection
- No production write-back
- No PHI
- No company production data
- No autonomous approval or release
- No dispensing or administration
- No real product transfer or shipment
- No physical wearable integration
- No Azure production deployment
- No regulatory-validation claim

## Step 164 authorization gate

Step 164 must not begin until an accountable human explicitly authorizes the local synthetic First-Tier Triad Assurance Orchestrator and Evidence Passport API.

**STEP 163 FIRST-TIER TRIAD OPERATIONALIZATION SCOPE REVIEW COMPLETE**

**STEP 164: AWAITING EXPLICIT HUMAN AUTHORIZATION**

